From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Malaria Vaccine Clinical Trial Begins

by Global Biodefense Staff
November 4, 2015
Malaria Infected Red Blood Cells

The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria.

The clinical trial is being conducted at Southampton, the lead trial site, and Oxford. It is a dose escalation study, where amounts of the potential vaccine are increased. The study will assess the safety of the vaccine candidate in people and its ability to generate immune responses that inhibit the growth of malaria eggs in mosquitos, preventing transmission of malaria.

The MosquirixTM vaccine candidate, developed by the team led by Dr. Sumi Biswas at the Jenner Institute, University of Oxford, is composed of a transmission-blocking antigen from Plasmodium falciparum, the more dangerous form of malaria.

The antigen is combined with Imaxio’s pro-immunogenic technology IMX313, designed to increase immune responses, and two viral vectors, which are virus carriers modified to be harmless but which can transport the vaccine elements into the body’s cells. One of those is a proprietary viral vector from Okairos (acquired by GSK in 2014). It is being administered through a course of treatment developed by the Jenner Institute in Oxford.

“Blocking transmission of malaria by mosquitoes from human to human is increasingly seen as one several complementary ways to fight this very important disease.” said Prof. Adrian Hill, Director of the Jenner Institute at Oxford University. “The malaria vaccine program at the Jenner Institute is now unique in having vaccines against all stages of the parasite’s life cycle in clinical development. The combination of technologies from Oxford, Imaxio & GSK is a very promising way to develop a transmission blocking vaccine candidate.”

Around half the world’s population is at risk of malaria and the disease led to an estimated 584,000 deaths in 2013.

Editor Also Recommends:

  • World Health Organisation right to be wary about first malaria vaccine (Global Fund)
From Our Partners
Tags: Malaria

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
Biosecurity

Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies

June 14, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC